This summary is generated by an algorithm. If you find any mistakes, let us know.

Biotechnology Life Science North America Therapeutics

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Source
Biotechnology Health Care Life Science Medical North America Software

PhenoTips Closes CAD $2.5M Funding Round Led by GreenSky Capital for Software to Transform Medical Genetics

– PhenoTips announced that it has raised CAD $2.5m in an oversubscribed seed fundraising round led by the GreenSky Accelerator Fund IV.
– The round includes the support of the Toronto Innovation Acceleration Partners, Thin Air Labs, Yorkville Partners, and angel investors including members of the GreenSky President’s Club.
– PhenoTips empowers healthcare providers to deliver precision medicine with the most complete and interoperable software solution for medical genetics.
– The company plans to double the size of its twelve-person Canada-based team and expand its cloud-based product offerings.

Source
Biotechnology Life Science Manufacturing North America Pharmaceutical

SmartLabs Announces $250 Million Series B and Update of Proprietary Laboratory OS

– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, announced the raise of a $250m Series B financing.
– The funding round was led by ArrowMark Partners. New investment partners include Winslow Capital Management and Onex Falcon, joined by existing investors Conversion Venture Capital (CVC2) and Breed’s Hill Capital.
– The funding will fuel the company’s accelerated growth, with a plan to scale operations to 2m sq ft within five years.
– In addition, SmartLabs announced the launch of the fourth version of its proprietary laboratory operations system (SmartLabs OS) which was first pioneered and introduced in 2016.

Source
Biotechnology Genetics Health Care Life Science North America

African genomics startup 54gene raises $25M to expand precision medicine capabilities

– African genomics startup 54gene has raised $25m in Series B funding.
– Pan-African venture capital firm Cathay AfricInvest Innovation Fund led this round.
– Lead investor from the company’s Series A funding, Adjuvant Capital, invested once again with participation from other VCs including KdT Ventures, Plexo Capital, Endeavor Catalyst and Ingressive Capital.
– The company has raised a total of $45m since its inception.

Source
Biotechnology Life Science North America

Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

– Walking Fish Therapeutics, a leader in B cell engineering, announced the close of $50M Series A financing— led by Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.
– Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells’ capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.

Source
Biotechnology Genetics Health Diagnostics Life Science North America

Mammoth Biosciences Raises $195 Million to Build Next-Generation CRISPR Products in Therapeutics and Diagnostics

– Mammoth Biosciences has secured $195m in financing, joining the select ranks of “unicorn” startups with a valuation of more than $1bn.
– The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
– Mammoth’s CRISPR platform leverages the largest toolbox of novel Cas enzymes, driven by its proprietary protein discovery engine which leverages the natural diversity of life.

Source
Biotechnology Life Science Southeast Asia

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

– Neuroglee Therapeutics, a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10m Series A led by Openspace Ventures and EDBI.
– The funding will be used to launch virtual neurology clinics and to support Neuroglee’s move to Boston.
– Other participants included Ramen Singh, the former chief executive officer of Mundipharma; Biofourmis co-founders Kuldeep Singh Rajput and Wendou Liu; and Eisai, the Japanese pharmaceutical that led Neuroglee’s last round last year.
– Neuroglee’s adaptive learning tech uses machine learning and biomarkers related to cognitive function, mood and behavior to automatically personalize therapy plans for each patient, who access the software through a smartphone or tablet.

Source
Biotechnology Life Science North America Therapeutics

Via Nova Therapeutics Raises $20M in Series A Financing

– Via Nova Therapeutics is an Oakland, Calif.-based company established to discover and develop therapeutics for acute and subacute viral infections.
– The company closed raised $20m in Series A financing.
Aditum Bio made the investment.
– The new investment will be used to advance the development of four preclinical antiviral programs in-licensed from Novartis.

Source
Life Science Pharmaceutical Western Europe

Provepharm Life Solution Raises €120M in Funding

– Provepharm Life Solutions, a Marseille-based pharmaceutical company that finds new applications for known molecules.
– The company raised €120M in funding.
Tikehau Capital will provide the funds joining the group’s pool of banking investors, including Société Générale, BNP Paribas, Banque Populaire Méditerranée, Crédit Agricole Alpes Provence and Bpifrance.
– The new investment will be used to consolidate its position as an international and independent pharmaceutical group, specifically by hiring new staff in France and the United States, and increasing the size of its laboratories in Marseille.

Source
Australia and Oceania Biotechnology Health Care Life Science Medical

HaemaLogiX Raises $10M in Funding

– haemaLogiX from Sydney is a biotech company developing a drug to treat a rare blood disorder.
– The company raised $10M in Series A funding.
– The round was led by Platinum Asset Management via its Platinum International Health Care Fund.
– The investment will be used to support the manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.

Source
Big Data Cloud Computing Life Science Software Western Europe

Seqera Labs grabs $5.5M to help sequence COVID-19 variants and other complex data problems

– Seqera Labs, a Barcelona-based data orchestration and workflow platform tailored to help scientists and engineers order and gain insights from cloud-based genomic data troves, as well as to tackle other life science applications that involve harnessing complex data from multiple locations, has raised $5.5 million in seed funding.
Talis Capital and Speedinvest co-led this round, with participation also from previous backer BoxOne Ventures and a grant from the Chan Zuckerberg Initiative.

Source
Biotechnology Health Care Life Science Medical North America

Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market

– Emulate, Inc. announced the close of an $82m Series E financing round.
– The round was led by Northpond Ventures with additional participation from Perceptive Advisors.
– With this investment, Emulate has raised nearly $225m to date.
– Emulate develops and manufactures next-generation in vitro models that enable researchers to replicate and study human biology and disease, helping them understand and predict drug response with greater precision and detail than possible with conventional cell culture or animal-based methods.
– Organ-on-a-chip technology by Emulate provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.

Source
Biotechnology Clinical Trials Life Science Western Europe

EnteroBiotix Raises $21M in Series A Funding

– EnteroBiotix is a biopharmaceutical company based in Glasgow, Scotland.
– The company raised $21m in Series A funding.
– The round was led by Thairm Bio with participation from Kineticos Ventures, Scottish Enterprise and SIS Ventures.
– The new investment will be used to advance the company’s microbiome drug pipeline and product development and manufacturing capabilities and grow its headcount to around 50.

Source
Biotechnology Life Science Western Europe

ILC Therapeutics Announces Successful Completion of £3.5m Funding Round

– ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a £3.5m funding round.
– Investors include Los Angeles-based lawyer and investor, Robert Kopple; St Andrews-based Eos Angel Investment Syndicate; Scottish Enterprise; ILCT management.
– Chairman Peter Bains said: “We are very pleased to complete this important funding round and to strengthen the Board with the appointment of Robert Kopple, Professor David Harrison and Chris Brinsmead. With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte™ through IND enabling studies in preparation for clinical trials as an anti-viral therapeutic for Covid 19.

Source
Life Science North America Therapeutics

CoRISMA Raises $27M in Series A Funding

– CoRISMA, a New Haven CT-based stage medical device company, raised $27M in Series A funding.
– The round was led by China Grand Pharmaceutical and Healthcare Holdings Limited.
– The company intends to use the funds to accelerate development and expand availability of the CoRISMA cardiac treatment device.

Source
Biotechnology Life Science Medical North America Pharmaceutical

Versanis Bio Raises $70M in Series A Financing

– Versanis Bio is an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
– The company closed a $70m Series A financing.
– The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
– The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.

Source
Genetics Health Care Life Science Medical North America

Genome Medical Announces Closing of $60 Million Series C Financing

– Genome Medical, the leading nationwide genomic care delivery company, announced the closing of a $60m Series C financing to accelerate commercial traction and advance its mission of transforming health care for all through genomic medicine.
– These strategic initiatives solidify its position as the preeminent technology-enabled provider of genetic health services and genomic insights.
– Genome Medical will use the financing proceeds to expand its team and further enhance the development of its configurable technology solutions to provide innovative and efficient genomic medicine programs.
– The company will continue to build out its full suite of physician services, test ordering capabilities and guidelines-based care plans to ensure comprehensive, seamless care for patients.

Source
Biotechnology Health Care Life Science Medical North America

Known Medicine Raises $7.2M in Seed Funding

– Known Medicine is a Salt Lake City, Utah-based 3D cell culture data set company.
– The company raised $7.2M in seed funding.
– The round was led by Caffeinated Capital, with participation from Khosla Ventures, Cota Capital, Kickstart, Forward VC, OATV, Y Combinator, Chris Gibson and Nish Bhat.
– The new investment will be used to grow the company’s proprietary 3D cell culture data set for deployment in partnership with biopharmaceutical companies and in the clinical diagnostics space.

Source
Biotechnology Life Science North America Therapeutics

Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Source
Biotechnology Health Care Life Science North America Therapeutics

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Source
Biotechnology Life Science North America

GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.

Source
Biotechnology Health Care Life Science North America

Syntr Health Technologies Raises $2.2M in Seed Funding

– Syntr Health Technologies, Inc. is a medical device company based in Irvine, California.
– The company raised $2.2m in seed funding.
– Backers included previous investors, angels and surgeons.
– The company intends to use the funds to build out sales for its patented, FDA-cleared SyntrFuge System™.

Source
Artificial Intelligence Big Data Biotechnology Clinical Trials Enterprise Enterprise Software Health Care Life Science Machine Learning North America Pharmaceutical

Intelligencia Raises $12M to Reduce the Risk of Clinical Research, Improve R&D Productivity, and Accelerate Scientific Breakthroughs

– Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base.
– Healthtech investor MTIP led the oversubscribed Series A round, joined by several of the company’s existing investors, including Big Pi Ventures and Synetro Group. ZS, a global professional services firm that leverages deep analytics and biopharmaceutical industry expertise to help companies and their customers thrive, has also participated in this round.
– The company’s founders, Dimitrios Skaltsas and Vangelis Vergetis, met while at McKinsey & Company, and have spent more than a decade in the intersection of clinical development, data science, and technology solutions.

Source
Biotechnology Life Science North America Pharmaceutical

Navrogen Raises $3.0M in Seed Funding

– Navrogen, Inc. from Cheyney, Pa. raises $3.0M in equity financing.
– The financing was led by Tellus BioVentures along with existing investors.
– The company intends to use the funds to advance its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities.

Source
Biotechnology Life Science North America

XinThera Closes $50M Series B Financing

– XinThera, a company focused on building a small molecule oncology and immunology pipeline, announced that the company has raised $50M in Series B financing.
– New investor Orbimed Advisors, LLC joined existing investors Foresite Capital and TTM Capital, bringing the total financing raised to $80M.
– The funds will be used to support the firm’s recruiting efforts and build its product pipeline.
– XinThera brings together a founder and investors that previously worked together to incubate, fund and launch Kinnate Biopharma, a company that progressed from idea to IPO in less than three years.
– Stephen Kaldor, Ph.D., co-founder and chairman of XinThera has more than 25 years of experience in creating meaningful medicines and shareholder value.

Source
Biotechnology Life Science North America

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

– InterVenn Biosciences announced the completion of a $201m Series C financing.
– The funding round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
– The proceeds from the financing will be used to accelerate development and commercialization of Dawn, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform.
– To date, the InterVenn glycoproteomics platform has been used to develop 16 clinical use cases across oncology and other indications. Dawn is currently under development and is planned to be commercialized in 2022.

Source
Biotechnology Life Science North America Therapeutics

Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases

– Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing.
– Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune and inflammatory diseases and to further invest in and scale up manufacturing operations in order to support supply for initial clinical studies.

Source
Health Care Life Science Medical North America Pharmaceutical

Engrail Therapeutics Extends Series A Financing to $64 Million

– Engrail Therapeutics announced the close of a $32m Series A extension round bringing total investment in the company to $64m.
– The round was led by Nan Fung Life Sciences following their leadership of the original Series A raise.
– The Company will use the proceeds to finance the advancement of its diverse pipeline, including lead assets ENX-101, ENX-102 and internal preclinical programs.
– Engrail’s lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
– Engrail has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system.

Source
AgTech Biotechnology Genetics Health Care Latin America Life Science

Protera Announces Final Close of Its $10M Series A Led by Sofinnova Partners

– Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced the final close of its Series A financing, at $10 million.
– The round was led by Sofinnova Partners, a leading European life sciences venture capital firm specialized in healthcare and sustainability.
– Protera is currently scaling-up its manufacturing process and validating its protein-based ingredients with several multinational companies.
– In particular, the financing will fast-track the scale up of protera guard™, a protein that extends the shelf-life of foods and replaces widely used chemical ingredients, with an efficient natural alternative.

Source
Biotechnology Eastern Asia Innovation Management Life Science

OriCiro Genomics Raises ¥800M in Series B Financing

– OriCiro Genomics is a Tokyo, Japan-based pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology.
– Series B ¥800m round led by The University of Tokyo Edge Capital Partners (UTEC) with participation of ITOCHU Technology Ventures.
– Also received a ¥200m long-term loan from Japan Finance Corporation (JFC), a government-affiliated financial institution, totaling ¥1b in this round of financing.

Source
Biotechnology Health Care Life Science North America

TMRW Life Sciences Raises $105M in Funding

– TMRW Life Sciences, Inc., a NYC-based life sciences technology company providing an automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), completed a $105m Series C equity and debt financing.
– The equity round was led by Transformation Capital with participation from GV (formerly Google Ventures), Casdin Capital, Peter Thiel, Anne and Susan Wojcicki, and existing investors 5AM Ventures and Life Sciences Innovation Fund, among others.
– The company intends to use the funds to accelerate global expansion, advance product innovation, develop consumer awareness of the platform, and support future business development opportunities.

Source
Biotechnology Life Science North America

Kriya Therapeutics Completes $100 Million Series B Financing to Advance Its Fully Integrated Platform for Designing, Developing and Manufacturing Transformative Gene Therapies

– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.

Source
Biotechnology Life Science North America Therapeutics

MOBILion Systems Raises $60M in Series C Funding

– MOBILion System from Chadds Fords develops high-resolution instrumentation for biomarker discovery.
– The company raised $60M in Series C funding.
– The round was led by D1 Capital Partners with participation from aMoon, Agilent Technologies, IP Group, Hostplus and Cultivation Capital.
– The new investment will be used to scale the commercialization of MOBIE® and advance product development for expansion into bioprocessing and multiomic biomarker discovery markets.

Source
Biotechnology Genetics Life Science Pharmaceutical Western Europe

MiNA Therapeutics Receives $15M Equity Investment from Eli Lilly and Company

– MiNA Therapeutics Limited is a London, UK-based provider of small activating RNA therapeutics.
– Company received $15m equity investment from Eli Lilly and Company.
– The funds will be used to advance and expand its internal pipeline of saRNA therapeutics.

Source
Biotechnology Health Care Health Diagnostics Life Science North America Pharmaceutical

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

– Xilis, Inc. announced the close of a $70m Series A financing.
– The round was led by Mubadala Capital and joined by new investors including GV, LSP, Catalio Capital Management, and Duke Angel Network.
– Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures, and Alix Ventures also participated.
– Xilis is based on decades of biomedical, oncology, and stem cell research by its three co-founders.
– Dr. Clevers, a Breakthrough Prize winner, is the inventor and pioneer of the organoid technology.
– Dr. Shen and Dr. Hsu are accomplished engineering and medical professors at Duke University and experts in precision medicine.

Source
Biotechnology Life Science North America Pharmaceutical

Psilera Raises $2.5M in Seed Funding

– Psilera Inc., formerly Psilera Bioscience, a Tampa, FLA.-based biotechnology company specializing in the clinical development of psychedelics and analogues, raised $2.5m in seed funding.
– The round was led by Iter Investments with participation from Baird, Inc., JLS Fund, Receptor, What If Ventures, as well as the company’s Founders and Board of Directors.
– The company intends to use the funds for key scientific and clinical personnel hires, research, and general working purposes.

Source
Biopharma Biotechnology Life Science North America

Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

– Giiant Pharma inc. announced that is closed an additional financing of $750,000 from AQC Capital and $500,000 from CQDM for a total of $1.25 million.
– The preclinical-stage biotech Company’s also closed a Seed round of $13.5 million, co-led by Amplitude Ventures and Genesys Capital.
– This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
– Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. The team is also in active discussions with potential partners to expand its pipeline of precisely delivered drug therapeutics for gastrointestinal disease.

Source
Biopharma Biotechnology Life Science North America

Eikonoklastes Closes Series A Funding

– Eikonoklastes Therapeutics from Cincinnati, Ohio develops immunotherapies to treat a broad range of cancers beginning with Triple Negative Breast Cancer (TNBC), a lethal form of breast cancer that comprises 15% of all breast cancers.
– The company raised an undisclosed amount in Series A funding.
– The round was led by CincyTech with participation from New York-based Elk Capital Ventures, Jobs Ohio, Rev1, and other undisclosed investors.
– The new investment will be used to conduct Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.

Source
Artificial Intelligence Big Data Food and Beverage Food Processing Information Technology Life Science Machine Learning North America SaaS Software Supply Chain Management

Native.AI Raises $1.75M in Strategic Pre-Seed Funding

– Native.AI is a real-time market and consumer intelligence platform provider.
– The company raised $1.75m in strategic pre-seed funding.
– Backers included current and former leaders at several top companies and government agencies including Blue Apron, The Kellogg Company, USDA and more.
– The new funding will be used to develop the company’s AI-powered platform to uncover, analyze and act on customer feedback to improve product offerings.

Source
Life Science Medical North America

Mouse brains and more in 3D: Seattle microscopy startup lands $4M to visualize medical specimens

– Lightspeed Microscopy, a Seattle startup, raised $4m in a Series A financing round.
– The round was led by Dynamk Capital and joined by other investors.
– The company is developing an end-to-end microscopy system for pathologists.
– The platform adapts a type of microscopy commonly used for basic research to assess pathology specimens in three dimensions.

Source
Artificial Intelligence Biotechnology Education Health Care Information Technology Life Science Machine Learning Medical Neuroscience Software Western Europe

Aiforia Raises €25.2M in Series B Funding

– Aiforia from Helsinki provides AI-based solutions for clinical and preclinical image analysis in pathology.
– The company raised €25.2M in Series B funding.
– The round was led by Epredia, a subsidiary of PHC Holdings Corporation, with participation from Aktia Nordic Micro Cap and existing shareholders.
– The new investment will be used to strengthen the company’s global presence for pharmaceutical companies as well as develop and release new platforms for the diagnosis of the most common cancers in the world.

Source
Artificial Intelligence Clinical Trials Computer Vision Data Visualization Health Care Life Science Machine Learning Medical North America

Clinical AI Technology Leader Mendel Raises $18M in New Capital

– Mendel, the company behind the clinical AI platform that understands the unstructured, natural language content within medical documents, announced it has raised $18 million in Series A funding.
– The oversubscribed round was led by DCM, a global venture capital firm, with participation from OliveTree, Zola Global Investors and Millennium Technology Value Partners.
– Return investors include Launch Capital, SOSV, Bootstrap Labs and Chairman of UCSF Health Hub Mark Goldstein.
– Olive Tree Managing Partner, Nichola Eliovits, will join the board.
– The capital will help the company rapidly grow its business and sales team to keep up with the explosive demand for clinical AI technologies by healthcare organizations over the last year.

Source
Health Care Life Science North America

LifeQ Raises $47M in Funding

– LifeQ, a provider of biometrics and health information derived from wearable devices and used in health management solutions, raised $47m.
– The round was led by Invenfin, 4Di Capital, Allectus Capital, Mogul Capital, Tenhong Holdings, Analog Devices, Hannover Re, Convergence Partners, Stellar Capital Partners, Nedbank Corporate and Investment Bank, Delos, OneBio Seed Investment Fund, Virgin Group, Lireas, Allen & Co, and Acequia Capital.
– The new investment will be used to accelerate the company’s global expansion and development of new products.

Source
Biotechnology Life Science Medical Device North America Pharmaceutical SaaS Software

Qualio Secures $50 Million in Series B Funding To Help Innovative Life Sciences Companies Unite Speed with Quality

– Qualio announced a $50m Series B funding round led by Tiger Global.
Menlo Ventures also joined this round, alongside the following current Qualio investors: Frontline Ventures, MHS Capital, Operator Partners, Sorenson Ventures, and Storm Ventures.
– The latest round of funding will support Qualio’s efforts to expand accessibility of their electronic quality management software (eQMS) and services for life sciences customers at global scale and also fuel significant investment in product and engineering team growth.
– To date, Qualio has raised more than $63m.

Source
Biotechnology Health Care Life Science Therapeutics Western Europe

ExeVir Closes US$50M Series A Financing

– ExeVir from Ghent, Belgium develops single domain antibody therapies providing broad protection against viral infections.
– The company closed its Series A financing raising a total of US$50m.
– Led by Fund+, the round was also joined by VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest as well as several Belgian family offices.
– The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.

Source
Biotechnology Life Science North America

Appia Bio Raises $52M in Series A Financing

– Appia Bio, Inc. is a Los Angeles, CA-based biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
– The company launched from stealth with $52m in Series A financing.
– The round was led by 8VC with participation from Two Sigma Ventures and seed investors Sherpa Healthcare Partners and Freeflow Ventures.
– Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications.

Source
Biopharma Biotechnology Health Diagnostics Life Science Medical Therapeutics Western Europe

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Source
Life Science North America Pharmaceutical

Nanology Labs Secures $3 Million in Oversubscribed Seed Round

– Nanology Labs announced that its seed capital raise was oversubscribed at $3M.
– The round was led by FACIT with co-investors Creative Destruction Lab Angels, Ontario Brain Institute, Ontario Center of Innovation, and MEDTEQ.
– The capital will advance development of T-MX (aka Manganescan), a smart nanomedicine designed to overcome tumor hypoxia, a common cause of resistance in cancer treatment.
– The financing is timely as T-MX completes GLP-toxicology and GMP-manufacturing in readiness for a Ph1/2 study in patients with oligometastatic brain cancer, planned to start at the Princess Margaret Cancer Center, recognized internationally for expertise in tumor hypoxia.

Source
Biotechnology Life Science North America Robotics Software

Artificial Raises $21.5M to Accelerate Life Science Breakthroughs

– Artificial, a software company providing a first-of-its-kind lab automation platform, announced the close of their $21.5M Series A investment round.
– The round was led by M12, Microsoft’s venture fund, along with Playground Global and AME Cloud Ventures.
– Artificial will use the investment to accelerate product development, expand their world-class team, and further their life science partnerships so that scientific breakthroughs can happen faster and more efficiently.

Source
Biotechnology Life Science North America Therapeutics

Biotech Company Nuvalent Raises $135 Million

– Nuvalent is a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer.
– The company raised $135m in Series B funding.
Bain Capital Life Sciences led the round and was joined by Deerfield Management, Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital.

Source
Biotechnology Health Care Life Science North America

Flare Therapeutics Raises $82M in Series A Financing

– Flare Therapeutics is a biotechnology company based in Cambridge, Mass.
– The company raised $82m in Series A financing.
– The round was led by Third Rock Ventures with participation from Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors and Eventide Asset Management.
– The new investment will be used for further advancement of the company’s lead program in precision oncology toward the clinic.

Source
Aquaculture Biotechnology Innovation Management Life Science North America

Alss Secures $7M in Series B Funding

– Applied LifeSciences & Systems (ALSS) from Morrisville, NC, is a biomedical systems company that develops an automated individualized poultry vaccination system.
– Company raised $7m in Series B equity financing.
– The round was co-led by Merck Animal Health and Mountain Group Partners with participation from Oval Park Capital.
– The new investment will be used to accelerate the company’s commercialization of its automated and individualized poultry vaccination system.

Source
Biotechnology Health Diagnostics Life Science North America

KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors

– KIYATEC, Inc secured a $2.5m investment from Seae Ventures.
– The investment comes on the heels of other recent announcements of success for KIYATEC.
– The company’s platform has been shown to be clinically predictive for patient-specific response to chemotherapy and targeted agents, and it has been analytically validated in both ovarian cancer and high-grade gliomas.
– KIYATEC has the potential to significantly improve outcomes for patients and their providers, not just for one cancer type, but across many solid tumors.

Source
Biotechnology Life Science North America Pharmaceutical

ReAlta Life Sciences Raises $20M in Series A3 Financing

– ReAlta Life Sciences, Inc. from Norfolk, Virginia closed a $20m Series A3 financing.
– The round was led by Marathon Pharma with participation from existing investors and new, undisclosed investors.
– The company intends to use the funds to advance multiple programs addressing ALI and HIE, including lead candidate RLS-0071, into Phase 2 clinical trials.

Source
Biotechnology Health Care Life Science North America Therapeutics

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)

– Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing.
– With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.
RA Capital Management and Nextech Invest co-led the financing, with participation from a top-tier syndicate of funds, including Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, and Logos Capital.

Source
Biotechnology Life Science Western Europe

Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

– Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted with a EUR 20 million (approx. $24 million) seed financing.
– Anavo’s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class.
– The funds will be used to advance a proprietary drug discovery portfolio in oncology and establish a versatile and robust platform to address the target space broadly across multiple indications.
– Anavo’s leadership team, Dr. Birgit Zech and Dr. Gerhard Müller, are building on several years of joint experience in the biopharmaceutical industry and have demonstrated the ability to navigate rapidly emerging sectors in biopharma most recently as co-founders of Gotham Therapeutics.

Source
Biotechnology Enterprise Software Life Science North America Software

Benchling Raises $200M Series E To Accelerate Biotech R&D

– Benchling has raised $200m in Series E funding led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital and Elad Gil.
– Existing investors participated, including Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and Lead Edge Capital.
– The company will use the funding to aggressively invest in product development and global expansion to support enterprise customers.
– Since launching in 2012, more than 300,000 scientists and 1,000 R&D organizations around the globe have adopted Benchling’s cloud platform to manage massively complex experimental datasets and optimize R&D processes.

Source
Biotechnology Life Science Medical Device Western Europe

Lumicks Raises $93M in Series D Financing

– Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
– The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
– The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.

Source
Biotechnology Health Care Life Science North America

Lumeda Announces $4.3M in Series A

– Lumeda, a medical technology company, announced the closing of its $4.3M Series A financing.
– The round was led by Connecticut Innovations, with participation from Cycle Venture Partners and brings the total amount raised to date to $5.3m.
– Both firms, along with angel investors, participated in the company’s Seed funding round in early 2020.

Source
Biopharma Biotechnology Life Science North America

Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem

– Alloy Therapeutics announced a $75m Series C financing round.
– The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors including Mubadala Capital, the asset management arm of Mubadala Investment Company.
– Proceeds will extend Alloy’s platforms and services into adjacent biologic modalities and further expand access to Alloy’s capabilities to more partners and geographies around the world.
– Fabian Hansen, founder and Managing Director of US venture capital fund Presight Capital, will join as a member of Alloy Therapeutics’ board of directors.
– Alaa Halawa, co-head of Mubadala Capital’s US Ventures business, will join as a board observer.

Source
1 2
Crunchbase icon

Content report

The following text will be sent to our editors: